First-Pass Metabolism of THC
Why swallowing THC hits differently than smoking it, and why edibles are so easy to overdo.
First-pass metabolism is the single biggest reason edibles behave so differently from a joint. When you swallow THC, your liver converts a large chunk of it to 11-hydroxy-THC before it ever reaches your brain — a metabolite that's roughly as potent as THC itself and crosses into the brain readily. That's why 10 mg eaten can feel stronger, longer, and weirder than 10 mg inhaled. It's also why dose-response is so unpredictable person to person.
Plain-language summary
When you swallow THC, it doesn't go straight to your bloodstream. It gets absorbed from your gut and then routed through your liver before reaching general circulation. Your liver treats it like any other foreign chemical and starts breaking it down immediately. This is called first-pass metabolism.
Two things happen as a result:
- A large fraction of the swallowed THC is destroyed or transformed before it can reach your brain. Oral bioavailability is only about 4–20% Strong evidence [1][2].
- A big share of what does get through is converted into 11-hydroxy-THC (11-OH-THC), an active metabolite that also gets you high Strong evidence [3][4].
Inhaled THC skips this. It goes from lungs to bloodstream to brain in seconds, and 11-OH-THC is produced in much smaller amounts Strong evidence [3].
This pharmacokinetic difference — not some mystical 'edible high' — is why edibles feel qualitatively different, take an hour to kick in, and are so easy to overdose on.
> This article is not medical advice. It describes pharmacology, not treatment. Talk to a clinician before using cannabis medically, especially if you take other medications.
What's actually happening biochemically
After oral ingestion, Δ9-THC is absorbed slowly and erratically from the small intestine. Because it's highly lipophilic, absorption depends heavily on what you ate with it (fat content matters) Strong evidence [2][5].
Absorbed THC travels via the portal vein to the liver, where cytochrome P450 enzymes — primarily CYP2C9 and CYP3A4 — hydroxylate it at the 11 position to form 11-OH-THC Strong evidence [4][6]. 11-OH-THC is then further oxidized to 11-nor-9-carboxy-THC (THC-COOH), which is inactive but is what drug tests actually detect Strong evidence [3].
Key pharmacological points:
- 11-OH-THC binds CB1 receptors with affinity similar to THC and produces cannabimimetic effects in humans Strong evidence [4][7].
- After oral dosing, plasma concentrations of 11-OH-THC can approach or exceed those of parent THC. After inhaled dosing, 11-OH-THC concentrations are typically a small fraction of THC Strong evidence [3].
- Genetic variation in CYP2C9 (particularly the CYP2C9\3* allele) meaningfully changes THC exposure. Poor metabolizers show ~3-fold higher THC AUC after oral dosing Strong evidence [6].
- CYP3A4 inhibitors (ketoconazole, clarithromycin, grapefruit juice) and inducers (rifampin, St. John's wort) shift THC exposure, though the size of the effect in real-world edible use is not well characterized Weak / limited [8].
What we know well (strong evidence)
- Oral THC has low, variable bioavailability (~4–20%) compared to inhaled (~10–35%) Strong evidence [1][2].
- 11-OH-THC is psychoactive in humans, producing cannabis-like subjective effects when administered directly Strong evidence [7].
- Oral dosing produces disproportionately more 11-OH-THC relative to parent THC than inhaled dosing does Strong evidence [3].
- Onset after oral dosing is delayed (typically 30–120 minutes) and duration is longer (4–8+ hours) than inhalation Strong evidence [2][5].
- CYP2C9 genotype meaningfully affects oral THC exposure Strong evidence [6].
What might be true (weak or mixed evidence)
- '11-OH-THC is 2–3x more potent than THC.' This is widely repeated online and in some review articles. The original support comes from older animal studies and limited human data. Modern controlled human comparisons of equimolar THC vs 11-OH-THC are sparse. Calling 11-OH-THC 'much more potent' is an overstatement; 'similarly potent, possibly somewhat more potent at CB1' is closer to what the evidence supports Weak / limited [4][7].
- Fatty meals dramatically increase edible potency. Fat clearly increases absorption of cannabinoids in animal and small human studies, but the magnitude of clinical impact on a standard edible is not well quantified Weak / limited [5].
- Sublingual/buccal products meaningfully 'bypass' first pass. They partially do, but many sublingual tinctures are actually swallowed and behave like edibles. True buccal absorption (as with nabiximols) does reduce first-pass metabolism, but the fraction absorbed sublingually vs swallowed in a typical consumer tincture is often unclear Weak / limited [9].
- Clinically important drug-drug interactions via CYP3A4/CYP2C9. Plausible and demonstrated in pharmacokinetic studies, but real-world clinical outcome data are limited Weak / limited [8].
What's folklore or wrong
- 'Edibles produce a fundamentally different type of high because they hit different receptors.' No. Same receptors (primarily CB1). The difference is pharmacokinetics and metabolite mix, not novel targets Strong evidence [3][4].
- 'Indica edibles are more sedating than sativa edibles.' The indica/sativa distinction doesn't reliably predict effects generally, and once THC is metabolized to 11-OH-THC the terpene content of the original flower is largely irrelevant to the systemic effect Disputed.
- 'You can't overdose on edibles, just wait it out.' You can't fatally overdose, but severe acute reactions (panic, tachycardia, vomiting, psychosis-like states, cannabinoid hyperemesis) are common and are driven substantially by first-pass pharmacokinetics: delayed onset → redosing → very high peak 11-OH-THC exposure Strong evidence [10].
What we don't know
- Quantitative contribution of 11-OH-THC vs parent THC to the subjective experience of an edible in typical consumers.
- How reliably CYP2C9 or CYP3A4 genotyping could predict a given person's edible response in practice.
- Whether commonly co-consumed compounds (CBD, other cannabinoids, alcohol, SSRIs) meaningfully alter first-pass THC metabolism at typical doses.
- The dose-response curve for 11-OH-THC-driven adverse events specifically.
Comparison with standard pharmacology framing
First-pass metabolism of THC is not exotic — it's the same phenomenon that makes oral morphine less potent than IV morphine, or that requires much higher oral than IV doses of propranolol. What's unusual about THC is that the primary hepatic metabolite (11-OH-THC) is itself strongly psychoactive, so first-pass doesn't just reduce potency — it changes the effect profile.
Compare:
- Oral morphine: first pass reduces potency; metabolites are less clinically relevant to the acute effect.
- Oral codeine: first pass is required for effect (CYP2D6 converts it to morphine). Genotype matters enormously.
- Oral THC: first pass reduces potency and generates a comparably active metabolite. Genotype matters moderately.
This is why 'just take the same mg orally' is a bad rule of thumb for anyone converting between inhaled and edible cannabis.
Risks and practical implications
- Delayed onset causes redosing. The single most common cause of edible ER visits Strong evidence [10]. Wait at least 2 hours before considering another dose.
- High interindividual variability. A dose safe for one person can be incapacitating for another. Genetics (CYP2C9), body composition, tolerance, gut contents, and co-medications all shift exposure Strong evidence [6].
- Drug interactions. If you take medications metabolized by or affecting CYP3A4 or CYP2C9 (warfarin, some SSRIs, some antifungals, some seizure meds), oral THC exposure can shift meaningfully. Talk to a pharmacist Weak / limited [8].
- Pediatric exposures. Edibles look like candy. Children who ingest them experience the same first-pass-driven 11-OH-THC surge with much smaller body mass, producing severe and sometimes hospitalizing effects Strong evidence [10].
> Reminder: this is educational information, not medical advice. Do not use it to self-manage a medical condition or to adjust prescribed medications. Consult a qualified clinician.
Sources
- Peer-reviewed Grotenhermen, F. (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical Pharmacokinetics, 42(4), 327–360.
- Peer-reviewed Huestis, M. A. (2007). Human cannabinoid pharmacokinetics. Chemistry & Biodiversity, 4(8), 1770–1804.
- Peer-reviewed Schwilke, E. W., Schwope, D. M., Karschner, E. L., Lowe, R. H., Darwin, W. D., Kelly, D. L., Goodwin, R. S., Gorelick, D. A., & Huestis, M. A. (2009). Δ9-Tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. Clinical Chemistry, 55(12), 2180–2189.
- Peer-reviewed Watanabe, K., Yamaori, S., Funahashi, T., Kimura, T., & Yamamoto, I. (2007). Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sciences, 80(15), 1415–1419.
- Peer-reviewed Zgair, A., Wong, J. C., Lee, J. B., et al. (2016). Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. American Journal of Translational Research, 8(8), 3448–3459.
- Peer-reviewed Sachse-Seeboth, C., Pfeil, J., Sehrt, D., Meineke, I., Tzvetkov, M., Bruns, E., Poser, W., Vormfelde, S. V., & Brockmöller, J. (2009). Interindividual variation in the pharmacokinetics of Δ9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. Clinical Pharmacology & Therapeutics, 85(3), 273–276.
- Peer-reviewed Lemberger, L., Crabtree, R. E., & Rowe, H. M. (1972). 11-hydroxy-Δ9-tetrahydrocannabinol: pharmacology, disposition, and metabolism of a major metabolite of marihuana in man. Science, 177(4043), 62–64.
- Peer-reviewed Stott, C. G., White, L., Wright, S., Wilbraham, D., & Guy, G. W. (2013). A phase I study to assess the effect of the CYP3A4 inhibitor ketoconazole on the pharmacokinetics of a single dose of nabiximols oromucosal spray in healthy volunteers. European Journal of Clinical Pharmacology, 69(4), 825–834.
- Peer-reviewed Karschner, E. L., Darwin, W. D., McMahon, R. P., Liu, F., Wright, S., Goodwin, R. S., & Huestis, M. A. (2011). Subjective and physiological effects after controlled Sativex and oral THC administration. Clinical Pharmacology & Therapeutics, 89(3), 400–407.
- Peer-reviewed Monte, A. A., Shelton, S. K., Mills, E., et al. (2019). Acute illness associated with cannabis use, by route of exposure: an observational study. Annals of Internal Medicine, 170(8), 531–537.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.